For more than 30 years, Wendy Hauck, PhD, MSc has made significant contributions to the field of medicine, with a particular focus on oncology. Within her industry, she also wields expertise in immunology, drug development, preclinical and translational cancer research, precision medicine, rare diseases, and immunotherapies with an overall mission to provide new treatments to patients who need them urgently. The founder and president of Wendy Hauck & Associates since 2024, she serves as an adviser and consultant for biotech startups in the areas of oncology and rare diseases and develops treatments on a global scale. In this capacity, she interprets and analyzes data on drug development and clinical research through collaborations with oncologists, surgical oncologists, and pathologists.

Prior to launching her own company, Dr. Hauck established herself as an innovative, entrepreneurial, and strategic medical affairs leader beginning in the 1990s. She gravitated toward her profession as many of her family members, friends, and colleagues had been diagnosed with or died from cancer, ultimately earning a PhD in biochemistry and then completing coursework at the McGill Cancer Centre at McGill University. She was active as a postdoctoral research fellow at Montreal General Hospital and Jewish General Hospital before becoming a medical adviser of immunology, transplantation, and oncology at Novartis Hospital, where she would excel for seven years.

Dr. Hauck then served as the Director of Global Drug Development and Clinical Research at Neurochem, now known as Bellus Health, where she first encountered a common challenge faced by smaller biotech companies: the absence of products in the market. The company was dedicated to developing a neurology drug for the treatment of Alzheimer’s disease and her research led to the phase 2 development of a drug that addressed a rare disease linked to chronic inflammation; she formulated protocols and conducted several trials. Yielding promising results, the package was submitted for approval to the FDA, Canada, and Europe—however, due to financial constraints, an additional phase of trials couldn’t be completed. Despite this, she remained committed, knowing that her work was intended for the benefit of patients, which she consider her most notable achievement in her career.

Following this appointment, Dr. Hauck was active as a national medical science liaison with Lundbeck Canada, a senior regional medical liaison with Amgen Canada, Inc., and a regional medical liaison with Celgene Corporation. She has also been a science adviser with the Bristol-Myers Squibb Company and last excelled at Eisai Oncology Medical—where she held the roles of Global Associate Medical Director and Global Medical Director of global medical affairs and oncology between 2020 and 2024. Over the course of her accomplished career, she has contributed to several publications and received two patents—one for the treatment of renal disorders, diabetic nephropathy, and dyslipidemias, and one for formulations and methods for treating amyloidosis.

Dr. Hauck has consistently received company awards for her collaborative and results-driven work approach, as well as her initiative and teamwork skills. She attributes much of her success to her mother, who played a significant role in instilling in her that she could accomplish anything she set her mind to. She also received encouragement and support from her professors and supervisors throughout schooling, helping her to overcome the many challenges she faced along the way.

Looking toward the future, she aspires to join the faculty of a university and continue to help scientists develop treatments for cancer patients.